Evolution by innovation as a driving force to improve TCR-T therapies
Adoptive cell therapies continually evolve through science-based innovation. Specialized innovations for TCR-T therapies are described here that are embedded in an End-to-End Platform for TCR-T Therapy Development which aims to provide solutions for key unmet patient needs by addressing challenges o...
Main Author: | Dolores J. Schendel |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1216829/full |
Similar Items
-
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
by: Soumaya Karaki, et al.
Published: (2016-11-01) -
Heterogeneity of CD40 Expression in Different Types of High-Risk Endometrial Cancer Affects Discordant Prognostic Outcomes
by: Zhao N, et al.
Published: (2023-06-01) -
PD-L1 Inhibits T Cell-Induced Cytokines and Hyaluronan Expression via the CD40-CD40L Pathway in Orbital Fibroblasts From Patients With Thyroid Associated Ophthalmopathy
by: Zhibin Liu, et al.
Published: (2022-05-01) -
Reduced Relapse-Free Survival in Colorectal Cancer Patients with Elevated Soluble CD40 Ligand Levels Improved by Vitamin D Supplementation
by: Hiroshi Fujimoto, et al.
Published: (2023-10-01) -
Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma
by: Manal Mohamed Saber
Published: (2022-02-01)